Copyright
©The Author(s) 2023.
World J Clin Cases. Aug 6, 2023; 11(22): 5338-5343
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5338
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5338
Parameter (physiological range) | Hospital admission (October 2019) | Acquired haemophilia diagnosed (December 11, 2019) | Treatment start (cyclophosphamide + prednisone) | Clinical and laboratory remission (December 2019) | Laboratory relapse (rituximab, February 2020) | Last TURBT (June 2020) |
APTT-R (0.8-1.2) | 1.71 | 2.42 | 2.38 | 0.98 | 1.2 | 0.81 |
FVIII (50%-150%) | - | 2% | 0.8% | 81.6% | 32% | 206% |
Inhibitor FVIII (0.0-0.8 BU/L) | - | - | 33 BU/L | 0.8 BU/L | 1.0 BU/L | 0.3 BU/L |
Haemoglobin (120-160 g/L) | 118 g/L | 87 g/L | 86 g/L | 113 g/L | 113 g/L | 138 g/L |
Platelets (150-400) × 109/L | 293 × 109/L | 291 × 109/L | 403 × 109/L | 366 × 109/L | 340 × 109/L | 318 × 109/L |
INR | 1.0 | 1.04 | 0.87 | 0.88 | 0.93 | 0.93 |
Bleeding symptoms | - | Haematuria | Haematuria | - | - | - |
- Citation: Ryšánková K, Gumulec J, Grepl M, Krhut J. Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report. World J Clin Cases 2023; 11(22): 5338-5343
- URL: https://www.wjgnet.com/2307-8960/full/v11/i22/5338.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i22.5338